Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 36: 149-153, 1990;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delanghe, J. R.
Right arrow Articles by Wieme, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delanghe, J. R.
Right arrow Articles by Wieme, R. J.

Clinical Chemistry, Vol 36, 149-153, Copyright © 1990 by American Association for Clinical Chemistry

Mass concentration and activity concentration of creatine kinase isoenzyme MB compared in serum after acute myocardial infarction

JR Delanghe, AM De Mol, ML De Buyzere, IK De Scheerder and RJ Wieme
Department of Clinical Chemistry, University Hospital, Gent, Belgium.

We compared three current methods (immunoinhibition, "Isomune-CK" immunoprecipitation, and the Tandem-E CKMB II immunoenzymometric assay) for determination of creatine kinase (CK; EC 2.7.3.2) isoenzyme MB in serum. Although results inter-correlated well, the immunoinhibition assay gave higher activity values. Atypical CK forms did not interfere with the immunoprecipitation and immunoenzymometric methods. In acute myocardial infarction the catalytic properties of CK decreased with the enzyme's age, as reflected by a steady increase in activation energy of the catalyzed reaction. In septicemia patients with very low CK and CK- MB catalytic activity, mean CK-MB mass concentration exceeded the upper reference limit, suggesting an increased rate of loss of activity concentration in these patients' sera. Because of the assay's lesser susceptibility to conformational changes at the active site of the enzyme, we suggest that measurement of CK-MB mass concentration is better suited for infarct sizing than measurement of catalytic activity.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
R. H. Christenson, H. Vaidya, Y. Landt, R. S. Bauer, S. F. Green, F. A. Apple, A. Jacob, G. R. Magneson, S. Nag, A. H.B. Wu, et al.
Standardization of Creatine Kinase-MB (CK-MB) Mass Assays: The Use of Recombinant CK-MB as a Reference Material
Clin. Chem., September 1, 1999; 45(9): 1414 - 1423.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American Association for Clinical Chemistry.